GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America.
Five of the 16 countries that together account for 85 percent of the growth of [GSK's emerging markets] region are from Latin America
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
See our Cookie Privacy Policy Here